Page 2 - Pharma Sector

Medtech, pharma welcome duty relief, seek GST cuts on key inputs

Industry welcomes customs duty exemption on petrochemicals but urges GST relief on inputs and faster refunds to ease cost pressures amid West Asia disruptions

Indian drugmakers may lose up to $750 million if Iran war drags on

Indian pharmaceutical companies may face losses of up to $750 million if the West Asia conflict continues, amid supply chain disruptions and rising logistics costs

Glenmark takes direct control of Ryaltris sales in US from April 2026

Glenmark will directly manage Ryaltris sales in the US from April 2026, strengthening its innovation-led portfolio and expanding its commercial presence in the market

As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices

Drugmaker cuts prices of injectable semaglutide brands to expand access in India, but says no similar price reduction is planned for oral semaglutide brand Rybelsus

Corona Remedies acquires Wokadine from DRL, enters iodine market

Acquisition of Wokadine marks Corona Remedies' entry into India's Rs 648 crore povidone iodine segment, strengthening its specialty portfolio and distribution reach

Delhi HC directs unsold Olymviq doses to govt hospitals after 30 days

Court allows Dr Reddy's 30 days to clear stock, after which unsold Olymviq doses will be supplied to government hospitals in presence of Novo Nordisk representative

Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly

Pharmaceutical companies are increasingly turning to AI to accelerate R&D, betting on new modelling tools and automated labs to unlock efficiency gains across their pipeline

We've always been an India player, says Biocon MD Shreehas Tambe

Biocon Limited names Shreehas Tambe CEO, outlines AI-led, integration-driven strategy to boost global biosimilars and generics growth

CDSCO flags 4 spurious drugs, 194 fail quality tests in February 2026

CDSCO flagged four drugs as spurious and 194 as not of standard quality in February 2026, including widely used medicines, as part of routine surveillance

Lupin, Zydus partner to co-market semaglutide injection in India

Lupin and Zydus Lifesciences enter a licensing pact to co-market semaglutide injection in India, aiming to improve access to therapies for diabetes and obesity

Drugmakers may review shipment schedules to West Asia if conflict drags on

Indian drugmakers are reviewing shipment schedules and inventories for West Asia as escalating tensions threaten sea and air routes, raising freight costs and risking supply delays

Glenmark to launch generic sodium phosphates injection in US in April 2026

Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.

CDSCO tightens quality net with audits, scientific cadre overhaul

Planning to outsource GMP audits to agencies certified by QCI; onboard 1,500 experts to review drug applications

Morepen Labs wins ₹825 crore long-term CDMO deal with global drugmaker

Morepen Labs has secured a ₹825 crore multi-year CDMO mandate from a global pharma major, with supplies set to begin in 4-5 months and execution running through Q1 FY27

Expect Pen-G production capacity to touch 10k MT in 12 months: Aurobindo

Aurobindo Pharma is looking to ramp up the production of Penicillin-G to over 10,000 metric tonnes on an annual basis over the next 12 months, according to company CFO S Subramanian. The Hyderabad-based drug maker also expects its China-based manufacturing plant to break even in EBITDA in Q4 and meaningfully contribute to the bottom-line EBITDA in the next year. "The ramp-up of the facility (Pen-G) is progressing in line with expectations and is well-positioned to deliver a meaningful uplift in profitability over time. Based on our current production level, we expect to produce more than 10,000 metric tonnes on an annualised basis over the next 12 months," Subramanian told analysts in a call. The company's Pen-G facility, located in a SEZ at Kakinada in Andhra Pradesh, is expected to touch production capacity of 15,000 metric tonnes per annum over a period of time. "It is important to note that the yield levels are steady and improving consistently over time," Subramanian said. Th

Pharma exports rise 9.4% in FY25; industry eyes double-digit growth

The commerce ministry on Saturday said the country's pharma exports grew 9.4 per cent in 2024-25 to USD 30.47 billion and the industry is aiming for a double-digit expansion in 2026-27. Issues pertaining to pharmaceuticals exports were discussed between the government officials and industry during Chintan Shivir in Ahmedabad. The sector, currently valued around USD 60 billion, is projected to reach USD 130 billion by 2030. India ranks third globally by volume, with medicines exported to over 200 markets, and more than 60 per cent of exports destined for stringent regulatory markets. The US accounts for 34 per cent and Europe for 19 per cent of India's pharmaceutical exports. "The interaction underlined the government's focus on enabling conditions for sustained export acceleration, with industry indicating readiness to target double-digit growth in 2026-27," it said. It added that exporters were also apprised of opportunities arising from recent trade engagements with key partner

India, Brazil set to sign pharma, aerospace, trade pacts during Lula visit

India and Brazil are poised to sign private-sector agreements across pharma, aerospace, ethanol and trade during President Lula's visit, as both nations expand cooperation in critical minerals and AI

Govt disburses ₹28,748 crore under 14 PLI schemes till December 2025

The government has disbursed Rs 28,748 crore under PLI schemes for 14 sectors, including electronics and pharma, since the launch of the support measure to boost domestic manufacturing, the government on Friday said. In 2021, the government announced Production-Linked Incentive (PLI) schemes for 14 sectors with an outlay of Rs 1.97 lakh crore. As many as 836 applications across 14 sectors, involving cumulative investment of over Rs 2.16 lakh crore, have been approved under the production linked incentive (PLI) scheme as of December 2025, It said that these sectors have registered a cumulative sales of over Rs 20.41 lakh crore, and exports of over Rs 8.3 lakh crore, the commerce and industry ministry said. It has generated employment for more than 14.39 lakh people. "Rs 28,748 crore (has been) disbursed as on December 31, 2025," it said. The 14 sectors include large scale electronics manufacturing, IT hardware, bulk drugs, medical devices, pharmaceuticals, telecom and networking .

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Sec sees upside in pharma, hospitals; Lupin, Aurobindo among top bets

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution